El Dr. Joshua Hustedt comenta sobre el impacto de las comorbilidades en las complicaciones y los costos en la artroplastia total articular

Este artículo es originalmente publicado en:


In this era of changing reimbursement models, every aspect of total joint replacement is under scrutiny.

Joshua Hustedt, MD, MPH, and his colleagues at Banner University Medical Center and Mayo Clinic in Phoenix, Arizona, recently examined the role of comorbidities in complications after primary and revision total hip and total knee arthroplasty, as well as the impact of these complications on the cost of care.

Their findings left them wondering: Will we reach a point at which it will be difficult for surgeons to justify performing total joint replacement on patients with multiple comorbidities, knowing they’re at higher risk for costly complications?

Click the image above to hear Dr. Hustedt’s comments on their study, “Calculating the Cost and Risk of Comorbidities in Total Joint Arthroplasty in the United States” (Paper 755), which was presented at the 2016 Annual Meeting of the American Academy of Orthopaedic Surgeons in Orlando.

Producer: Henrik B. Pedersen, MD; Director: Michael Bugera; Post Production: Charles J. Maynard
Todos los derechos reservados para:

Copyright 2016 International Congress for Joint Reconstruction